NEW YORK (GenomeWeb) – Horizon Discovery today announced it has amended its license with ERS Genomics for CRISPR/Cas9-edited cell lines, gaining full commercial rights to use CRISPR-edited cell lines in manufacturing therapeutics.

ERS Genomics is a company set up to commercialize the CRISPR/Cas9 intellectual property rights assigned to Emmanuelle Charpentier, of the Max Planck Institute for Infection Biology in Berlin.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.